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Abstract
Objectives. Multiple sclerosis (MS) is a neurodegenerative disease
characterised by inflammation and damage to the myelin sheath,
resulting in physical and cognitive disability. There is currently no
cure for MS, and finding effective treatments to prevent disease
progression has been challenging. Recent evidence suggests that
activating kappa opioid receptors (KOR) has a beneficial effect on
the progression of MS. Although many KOR agonists like U50,488
are not suitable for clinical use because of a poor side-effect profile,
nalfurafine is a potent, clinically used KOR agonist with a favorable
side-effect profile. Methods. Using the experimental autoimmune
encephalomyelitis (EAE) model, the effect of therapeutically
administered nalfurafine or U50,488 on remyelination, CNS infiltration
and peripheral immune responses were compared. Additionally, the
cuprizone model was used to compare the effects on non-immune
demyelination. Results. Nalfurafine enabled recovery and
remyelination during EAE. Additionally, it was more effective than
U50,488 and promoted disease reduction when administered after
chronic demyelination. Blocking KOR with the antagonist, nor-BNI,
impaired full recovery by nalfurafine, indicating that nalfurafine
mediates recovery from EAE in a KOR-dependent fashion.
Furthermore, nalfurafine treatment reduced CNS infiltration (especially
CD4+ and CD8+ T cells) and promoted a more immunoregulatory
environment by decreasing Th17 responses. Finally, nalfurafine was
able to promote remyelination in the cuprizone demyelination model,
supporting the direct effect on remyelination in the absence of
peripheral immune cell invasion. Conclusions. Overall, our findings
support the potential of nalfurafine to promote recovery and
remyelination and highlight its promise for clinical use in MS.
Keywords: cuprizone, experimental autoimmune
encephalomyelitis, kappa opioid receptor agonist, nalfurafine,
neuroinflammation, remyelination, transmission electron
microscopy, U50,488
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INTRODUCTION
Multiple sclerosis (MS) is a neurodegenerative
disease associated with chronic inflammation and
demyelination in the central nervous system (CNS).
It affects 2.5 million individuals worldwide and
often leads to debilitating motor, sensory,
autonomic and cognitive disabilities.1 MS is
considered an autoimmune disease involving the
trafficking of pro-inflammatory CD4+ and CD8+ T
cells into the CNS via the compromised blood–
brain barrier (BBB), resulting in lymphocyte
infiltration, microglia activation, focal
inflammatory demyelination, and axonal damage
by destroying the myelin sheaths formed by
oligodendrocytes (OLs).2,3
There is currently no cure for MS, and the
available immune-modifying medications are
capable of reducing the relapse rate but are
limited in their ability to halt disease progression
and promote CNS repair. Hence, new therapies
targeting different aspects of MS are highly
sought after. Targeting the remyelination process
has become a key area of interest in developing
novel MS therapies. During the early phase of MS,
remyelination can occur spontaneously within a
month or two after active demyelination.4
However, this spontaneous remyelination becomes
sparse and limited to the borders of the lesions
during the progressive stage of MS, as mature OLs
fail to remyelinate.
The kappa opioid receptor (KOR) is expressed
widely throughout both the human brain and
spinal cord.5–7 In the periphery, studies have
found KORs in the rat GI tract, adrenal gland,
kidney, lung, testis, ovary and uterus.8,9 KOR
expression has also been described on numerous
immune cell populations.10 Previous work has
identified kappa opioid receptor agonism as a
novel and clinically relevant therapy for
enhancing oligodendrocyte progenitor cell (OPC)
differentiation and remyelination. Du et al. (2016)
revealed that KOR knockout mice exhibit a more
severe disease phenotype in the experimental
autoimmune encephalomyelitis (EAE) mouse
model of MS, accompanied by significant
demyelination and CNS infiltration, which
indicates a role of endogenous KOR signalling for
OL differentiation and myelination. Prophylactic
administration of the traditional KOR agonist,
U50,488, significantly reduced disease scores in
EAE and also decreased demyelination and
leukocyte infiltration into the spinal cord. U50,488
was also shown to enhance remyelination in the
cuprizone-mediated demyelination model,11 while
Mei et al. (2016) found that U50,488 promoted
OPC differentiation and wrapping in a developed
micropillar array. Although these studies indicate
that U50,488 is beneficial, it causes undesirable
adverse effects including stress, dysphoria,
aversion, anxiety, depression, impaired learning,
and memory, all of which limit its clinical
potential.12,13 Hence, KOR agonism has the
potential to be a very promising target in the
treatment of MS for a KOR agonist with a
favorable profile.
Nalfurafine is the only KOR agonist in clinical
use and is significantly more potent than U50,488
in preclinical pain models.14 In addition,
nalfurafine is significantly more biased towards
the G-protein pathway activation compared to
U50,488 on both human and rodent KOR, with a
lower potency for p38 activation, which is
commonly associated with aversive side-
effects.15,16 Furthermore, long-term clinical trials
and post-marketing surveillance involving
intravenous or oral administration of nalfurafine
have shown it to be well-tolerated in humans17
and with fewer adverse effects in comparison to
U50,488.18 Here we investigated the ability of
nalfurafine to reduce disease and promote
remyelination in two animal models that
recapitulate aspects of MS- EAE, and cuprizone
intoxication.
RESULTS
Therapeutic treatment with nalfurafine
enabled functional recovery from EAE
Previous studies investigating KOR agonists in EAE
administered the agonists prior to the onset of
disease. This could be viewed as a limitation, as
the agonists could affect disease induction as well
as progression. Using a more clinically relevant
strategy, we investigated if nalfurafine was
effective when administered therapeutically (i.e.
upon the onset of EAE). We found that daily
treatment with nalfurafine (0.1–0.0003 mg kg1
intraperitoneally (i.p.) from disease onset (i.e.
disease score ≥ 1.0) caused a significant reduction
in disease burden when compared to vehicle-
treated animals (Figure 1a; P < 0.0001). A 2-way
ANOVA followed by the multiple comparisons test
was used to compare the scores of each dose of
nalfurafine to vehicle ( Supplementary figure 2).
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Therapeutic effects were most pronounced at the
0.03–0.01 mg kg1 dose of nalfurafine,
determined by significant and consistent recovery
from 10 days post-treatment (dpt). Although
nalfurafine did not alter peak disease
(Supplementary figure 3a), all doses of nalfurafine
reduced EAE-associated weight loss by the end of
the experiment (45 days post-immunisation; d.p.i)
compared to vehicle-treated mice (Supplementary
figure 3b).
To specifically assess recovery from paralysis,
animals were considered ‘recovered’ if they
reached a disease score of 0.5 or below (i.e. no
observable paralysis). Using this assessment, the
majority (71%, 27/38) of nalfurafine-treated
animals (0.01 mg kg1) fully recovered by day 23
post-treatment initiation (Figure 1b; P < 0.0001
compared to vehicle). In contrast, few vehicle-
treated animals recovered (7.5%, 4/53). In
addition, 0.01 mg kg1 nalfurafine led to the
greatest number of days in recovery (6.5  0.97
mean  SEM; P < 0.0001), whereas vehicle-treated
animals spent few days in recovery (0.3  0.14;
Figure 1c). To access relapses, ‘relapse’ was
defined by an increase in score by 1 full point
from the lowest score of the remission after peak
disease.19 We found that compared to vehicle
(0.49  0.07), nalfurafine reduced the number of
relapses per animal to day 23 post-treatment
initiation (Figure 1d), with the greatest effect
seen at the 0.01 mg kg1 dose (0.07  0.04;
P < 0.001). Overall, these results suggest that
therapeutic administration of nalfurafine is
effective at promoting full recovery of EAE and
reducing relapses. Nalfurafine at 0.01 mg kg1 led
to the most significant sustained recovery in EAE,
as determined by a consistent recovery of disease
scores and a dramatic reduction in relapse. Hence,
this dose was used for all following experiments.
Nalfurafine was more effective than
U50,488 at reducing disease
Since previous studies have shown that U50,488
significantly reduces disease in EAE, we evaluated
whether nalfurafine at 0.01 mg kg1 was similarly
effective as U50,488. Although prior research
administered U50,488 five days after
immunisation (i.e. before disease onset), upon
comparison with previously collated data, we
found that therapeutic treatment of EAE animals
with U50,488 (1.6 mg kg1 i.p. daily) also caused a
significant reduction in disease compared to
vehicle (Figure 1e; P < 0.0001). However, we
found that nalfurafine (0.01 mg kg1 i.p. daily)
was more effective at reducing disease than
U50,488 (P < 0.05). Moreover, U50,488 treatment
had no effect on peak disease compared to the
nalfurafine or vehicle groups (Supplementary
figure 3c; P < 0.01). However, within these
experiments, neither nalfurafine nor U50,488
ameliorated EAE-associated weight loss from the
time of treatment initiation (indicated by the grey
bar; 10–14 d.p.i) (Supplementary figure 3d). In
addition, recovery was more frequent with
nalfurafine compared to U50,488 (47%; 8/17;
Figure 1f). Both nalfurafine and U50,488
significantly enhanced the number of days spent
in recovery compared to vehicle (Figure 1g).
However, although the mean recovery rate for
nalfurafine-treated animals was greater than
U50,488 (4.4  1.6; P < 0.01), this did not reach
significance (P = 0.28). Furthermore, U50,488
treatment improved disease recovery but failed to
reduce relapses (0.66  0.18) compared to vehicle
(Figure 1h). Taken together, these results indicate
that nalfurafine has a greater therapeutic effect
than U50,488 in promoting disease recovery in
EAE.
KOR activation was involved in nalfurafine-
mediated recovery from EAE
To verify that amelioration of EAE by nalfurafine
is KOR-dependent, the KOR was blocked with a
highly selective and potent KOR antagonist, nor-
BNI. Upon disease onset, animals were
administered vehicle or nor-BNI (10 mg kg1 i.p.
weekly) and administered vehicle or nalfurafine
(0.01 mg kg1 i.p. daily) the following day. Nor-
BNI treatment did not alter any EAE parameters
(i.e. disease scores, peak disease) compared to
vehicle-treated animals (Figure 1i and
Supplementary figure 3e), indicating that
treatment with nor-BNI does not affect the
progression of EAE. In contrast, blocking KOR
with nor-BNI significantly impaired the ability of
nalfurafine to enable full recovery consistent with
nalfurafine treatment alone (Figure 1i;
P < 0.0001), although nalfurafine did still provide
some therapeutic benefit in terms of reduced
disease scores (P < 0.0001). Specifically, KOR
antagonism fully abolished recovery, with only
12.5% recovery (1/8 P < 0.01) compared to
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Figure 1. Treatment with nalfurafine was more effective than U50,488 at enabling functional recovery of EAE. Data are mean  SEM. A 2-way
(ANOVA) test was used for scoring data. A 1-way ANOVA with Holm–Sidak’s multiple comparison test was used for comparing treatment doses to
vehicle. *P < 0.05 **P < 0.01, **P < 0.001, ****P < 0.0001. (a) Disease scores of nalfurafine (0.0003–0.1 mg kg1) treated animals from disease onset
(score ≥ 1) to 23 dpt. Scores aligned to the day of disease onset (day 0 post-treatment). Mice were treated i.p daily with vehicle, or nalfurafine. Results are
combined from 12 independent experiments (n = 6–53, as indicated). (b) Percentage recovery to 23 dpt (recovery = score ≤ 0.5). (c) Number of days in
recovery to 23 dpt. (d) Number of relapses per mouse to 23 dpt (relapse = increase by 1 full point from the lowest score of remission). (e) Disease scores
of KOR agonist treated EAE to 23 dpt. Mice were treated i.p. daily with vehicle, U50,488 at 1.6 mg kg1, or nalfurafine at 0.01 mg kg1. Scores aligned
to day of disease onset. Results are combined from 12 independent experiments (n = 17–53). (f) Percentage recovery to 23 dpt. (g) Number of days in
recovery to 23 dpt. (h) Number of relapses per mouse to 23 dpt. (i) Animals treated i.p. with vehicle or nor-BNI (10 mg kg1) to induce full KOR
antagonism or vehicle, this continued once weekly thereafter. Animals also treated with i.p. injection one day following nor-BNI treatment with vehicle or
nalfurafine (0.01 mg kg1), and daily treatment continued thereafter. Results are combined from 2 independent experiments (n = 8 or 9). (j) Percentage
recovery to 23 dpt. (k) Number of days in recovery 23 dpt. (l) Number of relapses per mouse 23 dpt.
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nalfurafine alone (87.5%; 7/8) (Figure 1j), and
days spent in recovery (1.8  1.35; P < 0.01)
compared to nalfurafine alone (14.4  1.17)
(Figure 1k). Furthermore, nor-BNI abolished the
effect of nalfurafine on the relapse rate in EAE
such that the number of relapses per mouse
(0.87  0.29) was similar to vehicle (0.89  0.20)
(Figure 1l). Interestingly, nalfurafine/nor-BNI-
treated mice recovered from EAE-associated
weight loss compared to either nor-BNI alone or
vehicle (Supplementary figure 3f; P < 0.01). These
data confirm that KOR contributes to the disease-
modifying activity of nalfurafine.
Nalfurafine reduced lesion size and
promoted remyelination in EAE
In order to determine whether the observed
nalfurafine-mediated recovery was associated with
reduced lesion size and/or increased myelin, spinal
cord sections were stained with Black Gold II.
Using BlackGold II to determine myelin levels, we
found a significant increase in myelinated area in
nalfurafine-treated mice during chronic EAE (day
45) compared to peak disease (day 18), and this
difference was not observed in the vehicle-treated
mice (Figure 2b). Similar levels of demyelination
were observed at peak disease in the vehicle and
nalfurafine-treated groups, which suggests that
nalfurafine promoted significant remyelination by
day 45. The percentage lesion area in the white
matter was measured, (highlighted by the dotted
regions in Figure 2a) and showed consistent
lesions in vehicle-treated mice (Figure 2c).
Although there was a trend suggestive of a
reduction in lesion area with nalfurafine
treatment at day 45 compared to day 18, it did
not reach significance. The number of lesions per
mouse at day 45 compared to peak disease in the
nalfurafine-treated groups was also reduced, but
did not reach significance (Figure 2d).
For high-resolution analysis of myelin integrity in
the chronic phase of EAE, myelin thickness and
myelinated axon numbers were assessed by
transmission electron microscopy (TEM) with
representative images shown in Figure 2e. To
explore the impact of nalfurafine treatment on
myelination of axons, we compared the percentage
of myelinated and unmyelinated axons between
treatment groups (Figure 2f). There was an increase
in the percentage of myelinated axons
(86.4%  1.6; P < 0.05) and a decrease in the
percentage of unmyelinated axons (13.6%  1.6;
P < 0.001) in the group administered nalfurafine in
comparison to vehicle (69.6%  0.26 myelinated;
30.4%  0.26 unmyelinated). Demyelinated and
remyelinating axons in the EAE spinal cord are
identified by a thinner myelin sheath (i.e. higher g-
ratio), compared to those in a healthy spinal cord,
which have a g-ratio somewhere below 0.8.
Figure 2g shows a scatter plot of g-ratio as a
function of axon diameter for each group, with
trend lines reported. Lower g-ratios were seen for
all axon diameters in both healthy and nalfurafine-
treated mice compared to vehicle. We observed that
most healthy axons had a g-ratio in the range of
0.6–0.8, as expected (0.68  0.003). Axons from
vehicle-treated EAE mice had an increased mean g-
ratio compared to healthy, indicating demyelination
(0.75  0.004; P < 0.0001) (Figure 2h). The mean g-
ratio of axons from nalfurafine-treated animals
were significantly lower than vehicle (0.70  0.002;
P < 0.0001), and closer to healthy g-ratios,
indicating increased myelination. To determine the
extent of demyelination in these groups, we defined
a g-ratio above 0.8 as demyelinated or
remyelinating, according to Mei et al. (2016), and
found that most axons in the healthy group fell
below the 0.8 threshold (9.9%; Figure 2i). Vehicle-
treated animals had a significantly higher number
of axons above 0.8 (22.4%) compared to nalfurafine
(11.5%), which was similar to healthy. Consequently,
our results indicate that nalfurafine effectively
promotes remyelination during EAE.
Nalfurafine administration during chronic
EAE remained effective at promoting
functional recovery
To determine whether nalfurafine could promote
remyelination after chronic demyelination, animals
were treated from 10 days post-peak (dpp) EAE
disease and were randomly assigned to either
treatment group according to the time to reach
peak disease. We observed that initiating daily
treatment with nalfurafine at 0.01 mg kg1 at this
chronic EAE stage still enabled significant recovery
in EAE (Figure 3a; P < 0.0001; scores aligned to
disease peak). In this treatment, 23% (3/13) of
treated animals reached full functional recovery by
day 23 post-treatment, whereas no animals in the
vehicle-treated group fully recovered (0/12)
(Figure 3b). As expected, there was no difference in
peak disease between groups (Supplementary
figure 3g). In addition, delayed treatment with
nalfurafine promoted recovery from EAE-
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Figure 2. Nalfurafine reduced lesion size and promoted remyelination in EAE. Data are mean  SEM. A one-way ANOVA with Holm–Sidak’s
multiple comparison test was used for comparing groups. *P < 0.05 **P < 0.01, **P < 0.001, ****P < 0.0001. (a) Spinal cord sections assessed
by Black Gold II staining. Representative images of spinal cord sections from either age matched healthy animals (-EAE), EAE animals (+EAE)
treated with vehicle, or +EAE animals treated with nalfurafine (0.01 mg kg1) to day 45. Results are shown from 4 independent EAE
experiments, n = 5–11 mice per group. Each data point represents three sections from descending parts of the cervical spinal cord, averaged per
animal. (b) Percentage myelin area per animal determined by thresholding. (c) Percentage white matter lesion area per animal determined by
quantification of total area of lesions in the white matter spinal cord. (d) Number of white matter lesions per animal. (e) Representative TEM
images of spinal cord sections from either; –EAE age matched healthy animals, +EAE treated with vehicle or +EAE nalfurafine (0.01 mg kg1) to
day 45. Scale bar = 2 lm. Results are from 3 independent EAE experiments, n = 2–4 mice per group. (f) Percentage of myelinated versus
unmyelinated axons per group. Myelinated axons #P < 0.05 by 1-way ANOVA with Holm–Sidak’s multiple comparisons test. Unmyelinated axons
***P < 0.001, ****P < 0.0001 by 1-way ANOVA with Holm–Sidak’s multiple comparisons test. (g) Plots of inner axon diameter versus g-ratio
(inner axon diameter/outer axon diameter) fit with a linear function. (h) G-ratios per animal, along the x-axis each individual animal is defined as
H (healthy), V (vehicle) or N (nalfurafine). At least 200 axons per group were analysed. G-ratio analysis on at least 20 images per animal.
Significance is determined per treatment group. (i) Percentage of total axons with g-ratio of 0.8 or above.
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associated weight loss compared to vehicle
(Supplementary figure 3h; P < 0.05).
To determine whether nalfurafine promoted
myelination after chronic demyelination in the EAE
model, spinal cord axons were analysed by TEM,
and representative images from each treatment
group are shown in Figure 3c. We found a decrease
in the percentage of unmyelinated axons
(14.3%  3.8; P < 0.01) in the nalfurafine-treated
group in comparison to vehicle (22.9%  5.04)
(Figure 3d) as well as an increase in g-ratio in
vehicle-treated EAE axons (0.72  0.004; P < 0.05)
compared to healthy (0.7  0.003) (Figure 3e, f).
Nalfurafine-treated animals had significantly thicker
myelin layers (i.e. lower g-ratios) compared to
vehicle-treated mice, and this finding is supported
by a decrease in g-ratio (0.69  0.004; P < 0.01) and
decreased percentage of unmyelinated axons
compared to vehicle (Figure 3f, g). Consistent with
previous findings, no difference was detected
between nalfurafine-treated and healthy animals in
terms of g-ratio or percentage of unmyelinated
axons. Taken together, these findings indicate that
nalfurafine can promote remyelination even
following sustained demyelination in EAE.
CNS-infiltrating immune cells are reduced
by daily KOR-agonist administration in EAE
Since nalfurafine displayed significant therapeutic
responses in EAE, we assessed whether nalfurafine
altered the immune environment contributing to
EAE disease reduction. To evaluate immune
phenotype, we analysed splenic T-cell and myeloid
populations 45 days after EAE induction, (gating
strategy in Supplementary figure 4), but found no
difference in the proportions of CD4+ T cells, CD8+
T cells, or CD25+ regulatory T cells (Supplementary
figure 5a). CD25+CD4+ T cells were confirmed to
express FoxP3+, the key Treg transcription factor
(Supplementary figure 6). Additionally, there was
no difference in the proportion of cells in the
myeloid compartment, including CD11b+Ly6G-F4/
80hi macrophages, CD11b+Ly6Ghi neutrophils,
CD11b+Ly6C+ monocytes, or CD11b+CD11chiI-A/I-Ehi
dendritic cells (Supplementary figure 5b). Overall,
nalfurafine did not alter the major peripheral
immune cell populations in the spleen during
chronic EAE.
Inflammatory damage in the CNS during MS
and EAE is regulated by many cell types including
T cells, B cells, neutrophils, monocytes,
macrophages, and resident microglia. Figure 4a
shows the gating strategy for evaluating immune
cell infiltration into the CNS. We found similar
infiltration of immune cells (i.e. CD45high cells) at
peak disease (day 18) regardless of treatment, but
the neuroinflammation was reduced at chronic
EAE with nalfurafine treatment compared to
vehicle (Figure 4b; P < 0.05). This finding indicates
that nalfurafine treatment contributes to the
resolution of immune cell infiltration in the CNS.
To understand if specific immune cell populations
were differentially affected, we assessed CD4+ T
cells, CD8+ T cells, Tregs, and B cells as a frequency
of CD45int microglia using a sequential gating
strategy shown in Figure 4c. We also assessed
neutrophils, macrophages, monocytes, and
dendritic cells as a frequency of CD45intCD11b+
microglia using the sequential gating strategy
shown in Figure 4d. The number of
CD45intCD11b+ microglia (in myeloid gating
strategy) was comparable to CD45int microglia (in
lymphocyte gating strategy; Supplementary
figure 6). There was no difference in lymphocyte
populations between nalfurafine and vehicle-
treated groups at peak disease consistent with the
similar peak disease scores at day 18 (Figure 4e).
During chronic disease, nalfurafine treatment
resulted in a significant reduction in both CD4+
and CD8+ T cells (P < 0.05), but did not appear to
alter either CD25+ Treg or B-cell infiltration into
the CNS at chronic EAE. Furthermore, there was
no difference in myeloid cell infiltration between
nalfurafine and vehicle-treated groups at peak
disease or in the recovery phase of EAE
(Figure 4f). Overall, nalfurafine treatment alters
the CNS immune environment by reducing the
infiltration of CD4+ and CD8+ T cells into the CNS,
and this reduced T-cell infiltration may contribute
to the therapeutic effects of nalfurafine in EAE.
Presence of KOR agonists alters the
peripheral T-cell response
Although the abundance of splenic T-cell
populations was unaltered by nalfurafine
treatment, it was possible that KOR-agonist
treatment altered antigen-specific T-cell responses
given the reported immunomodulatory properties
of KOR agonists.20 Splenocytes from nalfurafine,
U50,488, vehicle-treated EAE animals and healthy
controls were isolated at day 45 post-
immunisation and stimulated ex vivo with either
myelin oligodendrocyte glycoprotein (MOG35–55)
peptide to assess antigen-specific responses or the
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Figure 3. Nalfurafine remained effective in promoting functional recovery in chronic EAE. Data are mean  SEM. A 2-way (ANOVA) test was
used for scoring data. 1-way ANOVA with Holm–Sidak’s multiple comparison test for comparing groups. *P < 0.05, **P < 0.01, **P < 0.001,
****P < 0.0001. (a) Disease scores of nalfurafine-treated EAE from 10 dpp to 23dpt, where scores are aligned to disease peak. Female, C57BL/6
mice were immunised to induce EAE as described and scored daily. Mice were treated from 10 dpp (day 0 post-treatment; indicated by the
dotted line at X = 0) with i.p injection daily with vehicle or nalfurafine (0.01 mg kg1). Results shown are combined from 3 independent
experiments (n = 12 or 13). (b) Percentage recovery to 23 dpt compared to vehicle (recovery = score ≤ 0.5). (c) Representative images of spinal
cord sections from either; –EAE age matched healthy animals, +EAE treated with vehicle or +EAE nalfurafine (0.01 mg kg1). Scale bar = 5 lm.
Results shown are from 3 independent EAE experiments, n = 2–4 mice per group. (d) Percentage of myelinated versus unmyelinated axons per
group. Unmyelinated axons **P < 0.01 by 1-way ANOVA with Holm–Sidak’s multiple comparisons test. (e) Plots of inner axon diameter versus g-
ratio (inner axon diameter/outer axon diameter) fit with a linear function. (f) G-ratios per animal, along the x-axis each individual animal is
defined as H (healthy), V (vehicle) or N (nalfurafine). At least 200 axons per group were analysed. Significance is determined per treatment group.
(g) Percentage of total axons which have a g-ratio of 0.8 or above.
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polyclonal T-cell mitogen, concanavalin A (ConA),
which leads to activation of T cells and the
production of cytokines. Splenocytes were
analysed for intracellular cytokine responses
(gating strategy in Supplementary figure 7).
Following in vivo treatment with KOR agonists
and in vitro stimulation, no significant changes
to CD4+ or CD8+ T-cell frequencies in response
to KOR-agonist treatment were found
(Supplementary figure 8a, b). In response to ConA
stimulation, the percentage of interferon (IFN)c+
CD4+ and CD8+ T cells was reduced by daily in vivo
nalfurafine treatment but not U50,488, suggestive
of a dampening of the Th1 response (Figure 5a, b;
P < 0.05). To determine whether nalfurafine
exerted a direct effect on T cells, splenocytes from
EAE animals (at day 28) were stimulated with
MOG35–55 peptide or ConA in the presence of
nalfurafine (50 nM), U50,488 (1 µM), or vehicle.
These doses were selected to be within a range
previously confirmed to have comparative pERK
signalling activity16 and within a range of 10–
100 nM found to alter cytokine activity on na€ıve
splenocytes (Supplementary figure 9).11,16,21
Following in vitro KOR agonist treatment, the
proportion of CD4+ or CD8+ T-cell populations
were similar between groups (Supplementary
figure 8c, d), whereas ConA-stimulation in the
presence of nalfurafine significantly decreased the
percentage of IFNc+ CD4+ T cells compared to
vehicle (Figure 5c). Furthermore, both nalfurafine
and U50,488 significantly reduced IFNc+ CD8+ T
cells following MOG35–55 stimulation and ConA
stimulation (Figure 5d).
In contrast to IFNc, nalfurafine treatment
in vivo or in vitro significantly reduced MOG35–55-
specific interleukin (IL)-17A expression by CD4+ T
cells (Figure 5e, f; P < 0.01), and while U50,488
treatment appeared to reduce IL-17A production,
the effect did not reach significance. We also
observed no difference in IL-17A expression in
CD8+ T cells (Supplementary figure 8e, f). Finally,
no change in IL-10 expression in CD4+ and CD8+ T
cells of EAE animals treated in vivo was detected
(Supplementary figure 8g, h); however, IL-10
increased following nalfurafine treatment in vitro
compared to U50,488 in unstimulated CD4+ and
CD8+ T cells (Figure 5g, h; P < 0.05). These data,
taken together, support immunomodulation by
KOR agonists with nalfurafine having a more
significant effect than U50,488 in shifting the
immune environment away from Th1 and Th17 to
a more regulatory response.
Nalfurafine drives remyelination in the
cuprizone model of disease
Since nalfurafine promoted functional recovery
and reduced CNS-infiltrating immune cells in EAE,
we assessed the effects of nalfurafine in the non-
immune-mediated demyelination model, the
cuprizone (CPZ) model. In this model, shown in
Figure 6a, mice were fed a CPZ diet for 42 days to
induce demyelination in the brain. The animals
were treated with nalfurafine or vehicle 7 days
before returning to standard pelleted chow until
the experimental endpoint (day 70).
Representative TEM images of the corpus callosum
collected at the experimental endpoint are shown
in Figure 6b, with 2 animals per group assessed.
There was a significant increase in the percentage
of myelinated axons in the healthy corpus
callosum (80.7%  2.0) compared to vehicle
(71.2%  2.2; P < 0.05), while treatment with
nalfurafine significantly increased myelinated
axons (80.4  1.2; P < 0.05) compared to vehicle.
Moreover, the percentage of myelinated axons in
the nalfurafine-treated corpus callosum was
similar to healthy. There was also a significant
decrease in the percentage of unmyelinated axons
(19.5%  1.0) in the group administered
nalfurafine in comparison to the CPZ vehicle-
treated group (28.8%  2.2; P < 0.001), while the
percentage of unmyelinated axons in the
nalfurafine-treated corpus callosum was again
similar to healthy (19.6  2.2) (Figure 6c). The g-
ratio of the animals administered nalfurafine
(0.73  0.076) significantly decreased in
comparison to the CPZ control group
(0.76  0.0057; P < 0.01) (Figure 6d, e). These
results indicate that nalfurafine treatment
significantly enhanced remyelination in the corpus
callosum following demyelination, even in the
absence of immune cells.
DISCUSSION
Recent work has shown that KOR agonists
significantly alleviate the symptoms of EAE and
promote repair of damaged myelin,11 but clinical
translation of the findings has been hampered by
the poor side-effect profile of these KOR agonists.
This study aimed to evaluate whether a clinically-
approved KOR agonist, nalfurafine, would be an
appropriate candidate to promote repair and
remyelination during MS. This study demonstrated
that nalfurafine, a potent KOR agonist, improves
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Figure 4. CNS-infiltrating immune cells were reduced by daily KOR-agonist administration in EAE. Shown are the results from 7 independent
experiments with 8–23 mice per group. Data are mean  SEM. The non-parametric Mann–Whitney test was used for comparing either peak EAE
or chronic EAE groups. *P < 0.05. (a) Analysis of lymphocyte populations from healthy, vehicle and nalfurafine (0.01 mg kg1) treated brain
tissue. All infiltrating immune cells were identified by CD45high expression. The relative number of cells is expressed as a ratio to microglia
(CD45intCD11b+). (b) Infiltrating cells identified by CD45high expression, at either day 18 (peak disease) or day 45 (recovery) post-immunisation.
(c) Identification of CNS-infiltrating lymphocyte immune cell types by a sequential gating strategy. Identification of B cells (CD45highCD3-B220+),
CD4+ T cells (CD45highB220CD3+CD4+), CD8+ T cells (CD45highB220CD3+CD8+), and Tregs (CD45highB220CD3+CD4+CD25+). (d) Identification
of CNS-infiltrating myeloid immune cell types by a sequential gating strategy. Identification of myeloid cells (CD45highCD11b+), neutrophils
(CD45highCD11b+GR1+), macrophages (CD45highCD11b+F4/80+), DCs (CD45highCD11b+Gr1-F4/80-CD11c+IA/IE+) and monocytes
(CD45highCD11b+Gr1-F4/80CD11c+IA/IE + Ly6Chigh/low). (e, f) Analysis of immune populations in the brain. The relative number of cells is
determined as a ratio to microglia (CD45intCD11b).
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clinical recovery when administered at the onset
of symptoms as well as in the chronic phase of
EAE. Moreover, the potential of nalfurafine as a
therapeutic option is highlighted by its
immunomodulatory effects as well as its
neuroprotective effects, which occur
independently. Finally, we report that the disease-
modifying effects of nalfurafine occur over a wide
range of doses and are superior to the prototypic
KOR agonist, U50,488.
While nalfurafine provides a significant benefit
over a wide range of doses (0.1–0.0003 mg kg1),
the 0.01 mg kg1 dose appears to be the most
effective at promoting disease recovery,
enhancing the time to recovery, and reducing
relapse rate. While U50,488 promoted recovery in
EAE as reported previously,11 this study is the first
to show that therapeutic administration of
U50,488 reduced EAE. Interestingly, while both
nalfurafine and U50,488 reduced disease and
enhance recovery, we also observed that in
contrast to nalfurafine, U50,488 enhanced the
relapse rate. The limited effect on disease relapse
suggests that the immunomodulatory effects of
U50,488 may not fully regulate the on-going
neuroinflammatory response.
To verify that nalfurafine alleviates the
symptoms of EAE through KOR activation, we
blocked the KOR with a highly selective and
potent KOR antagonist, nor-BNI, a dimeric
naltrexone derivative used as a standard tool in
opioid pharmacology.22,23 We showed that the
effect of nalfurafine was significantly inhibited,
reflected by disease scores, as well as in recovery
and relapse rates. Previous research has revealed
that the antinociceptive effects of the KOR
agonist U50,488 and the salvinorin A analog,
Mesyl Sal B can be blocked by a single injection of
nor-BNI (10 mg kg1 i.p.) in rats and mice.24,25
Interestingly, the effect of nalfurafine was not
completely abolished to the levels of the vehicle-
treated animals in terms of disease scores, with
the nalfurafine plus nor-BNI animals performing
significantly better than the vehicle or nor-BNI
single treatment. Although one possible
explanation could be that these weekly injections
of nor-BNI only partially blocked the KOR,
previous studies have demonstrated that weekly
injections of nor-BNI are sufficient to completely
block KOR activity due to the long-lasting and
selective effect of nor-BNI (i.e. a half-life of
~14 days in mice).26,27 Alternatively, these data
could indicate that there is another additional
mechanism, by which nalfurafine reduces EAE
disease, which is independent of nor-BNI
inhibition.
In MS, remyelination is impaired during the
chronic stage as a result of OPC differentiation
into mature OLs being halted.28,29 Promoting OPC
maturation into myelinating OLs is therefore
crucial for myelin repair. Previous reports11,21
demonstrated that a variety of KOR agonists
could improve oligodendrocyte differentiation
and myelination in EAE. These reports are
consistent with our study which showed that
nalfurafine-treated animals had a greater
myelinated area upon disease recovery (45 d.p.i)
in the spinal cord compared to vehicle-treated
animals (45 d.p.i). It is important to note that
extensive demyelination is evident at peak disease
(18 d.p.i), and is equal between treatment groups,
suggesting that nalfurafine does not inhibit
immune-mediated demyelination in the first few
days of administration. A large sample size of 5–
10 animals per treatment group give a robust
indication that nalfurafine is driving
remyelination in EAE. However, within these
analyses, there was a limit of 3 sections of the
spinal cord per mouse averaged for the
assessment. Future analysis with a larger sampling
region of the spinal cord would ensure that
lesions are not missed, and give a conclusive
representation of the full extent lesion areas in
each animal.
By TEM analysis, we observed that spontaneous
remyelination is ineffective in EAE to day 45,
represented by an increase in the percentage of
unmyelinated axons compared to myelinated
axons in the vehicle-treated group, in addition to
the high percentage of demyelinated axons
having a g-ratio above 0.8. In contrast,
nalfurafine-treated EAE animals had a recovery in
the number of myelinated and a decrease in
unmyelinated axons, suggesting nalfurafine can
restore myelination and axon integrity to healthy
levels. This finding is supported by the reduction
in the g-ratio by nalfurafine compared to vehicle
treatment, which indicates remyelination. As
g-ratios have been presented for each individual
animal in the analyses, there appears to be
variations in g-ratio in the healthy samples. Larger
axons tend to have higher g-ratios. This is the
case in this analysis, where g-ratio variability is
evident depending on mean axon diameter
(Supplementary figure 10). Previous literature has
reported that axonal diameters are generally
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Figure 5. Presence of KOR agonists alters the peripheral T-cell response. Data are mean  SEM. The 1-way ANOVA with Holm–Sidak’s multiple
comparison test was used for comparing treatments within each stimulation. *P < 0.05, **P < 0.01, **P < 0.001, ****P < 0.0001. (a, b) CD4+
and CD8+ T-cell intracellular interferon (IFN)c from splenocytes of EAE animals treated daily from onset with vehicle, nalfurafine (0.01 mg kg1)
or U50,488 (1.6 mg kg1). (c, d) CD4+ and CD8+ T-cell intracellular IFNc from splenocytes of MOG35–55 immunised animals to day 28.
Splenocytes were treated in vitro with vehicle (0.01% DMSO), nalfurafine (50 nM) or U50,488 (1 lM) for 72 h alongside stimulations. (e) CD4+ T-
cell intracellular interleukin (IL)-17A (as frequency of parent, CD4+) from splenocytes of EAE animals treated daily from onset with KOR agonists.
(f) CD4+ T-cell intracellular IL-17A (as frequency of parent, CD4+) from splenocytes of MOG35–55 immunised animals to day 28 and treated
in vitro with KOR agonists. (g, h) CD4+ and CD8+ T-cell intracellular IL-10 as mean fluorescence intensity (MFI) from splenocytes of MOG35–55
immunised animals to day 28 and treated in vitro with KOR agonists.
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< 2 lm, with a mean g-ratio of 0.6–0.7.11,21 Taking
this into account, g-ratios for healthy animals fell
within the range of typical g-ratios.
In MS, chronic and continuous inflammation
and demyelination drive the long-term
progression of deficits, and this process is
modelled by EAE.30 We found that nalfurafine
was effective in this chronic phase of EAE,
indicating that it not only halts further myelin
damage but also promotes myelin recovery after
chronic demyelination. While there was no
significant difference in the number of
myelinated axons between the EAE and healthy
animals, spontaneous remyelination may be
occurring during chronic EAE, allowing for
remyelination of demyelinated axons. However,
there is a clear increase in the number of
unmyelinated axons in vehicle-treated EAE
compared to the nalfurafine-treated group, which
correlates to the increase in g-ratio. Taken
together, these data suggest that nalfurafine may
be a promising candidate for the treatment of
chronic demyelinating disease such as MS, where
there is continuous inflammation and the
accumulation of neurological deficits.
Our results indicate that nalfurafine treatment
had little effect on the major peripheral immune
populations, which is consistent with previous
reports using U50,488 during EAE.11 As EAE
induces neuroinflammation, we explored the
effects of nalfurafine treatment on CNS-
infiltrating immune cells. By comparing CNS
infiltrates at peak EAE and chronic disease, we
showed that EAE-associated infiltration is
significantly reduced by daily nalfurafine
treatment. These findings are consistent with
Tangherlini et al.,31 who observed a reduction in
CD45+ cells in EAE following KOR agonist
treatment, which was absent in KOR-deficient
mice. In both MS and EAE, effector T cells cross the
BBB into the CNS to promote inflammation
leading to demyelination and axonal damage. We
found that nalfurafine treatment led to a
significant reduction of infiltrating CD4+ T cells
and CD8+ T cells, which are considered major
pathogenic contributors to EAE.30,32 Importantly,
this study is the first to report on the effects of
KOR agonists on CNS infiltrate subsets when
administered after the onset of disease and
supports the potential of nalfurafine to decrease T
cell-mediated neuroinflammation within the CNS.
The immunomodulatory properties of KOR
agonists have previously been explored,20,31,33 and
this work provides evidence to suggest that the
opioid system can interact with the immune
system.34 For example, Tangherlini et al.31
demonstrated that KOR agonist treatment
regulates effector T-cell activation following EAE
and the effect is dependent on binding to KOR.
Our study revealed MOG35–55-specific
downregulation of Th17 responses by nalfurafine
but not U50,488. Previous studies did not find that
U50,488 altered immune responses such as the
percentage of pathogenic cells in the CNS or CD4+
T-cell subsets or cytokine secretion.11 We also
found that MOG35–55-specific Th1 responses were
not significantly affected by nalfurafine, although
ConA-induced IFNc expression was significantly
reduced following in vivo or in vitro exposure. Our
findings along with those of Du et al. suggest that
U50,488 has only modest immunomodulatory
activity, and highlight that different KOR agonists
may have distinct patterns of activity.11 Further
work is necessary to investigate the mechanisms of
action of nalfurafine on the CNS.
IFNc is typically known to promote
differentiation of Th1 cells, directly contributing
to neuroinflammation in MS.35 Additionally, IFNc
production by CD8+ T cells has been reported as
an important factor driving EAE and MS,36,37 with
one particular study showing a significant excess
of IFNc-producing CD8+ T cells in MS lesions.38 We
saw significantly reduced expression of
polyclonally-induced IFNc in both CD4+ and CD8+
T cells exposed to nalfurafine in vivo or in vitro.
Additionally, IL-17A, another potent effector in
the pathogenesis of EAE,39,40 was significantly
reduced in a MOG35–55-specific manner by in vitro
and in vivo exposure to nalfurafine. Finally, IL-10,
which is recognised to suppress the development
of EAE,41,42 was increased in CD8+ T cells
following in vitro nalfurafine treatment. These
CD8+ T cells may exhibit a regulatory function
with cytokines like IL-10 promoting immune
response resolution.43 These data highlight the
influence of KOR agonists like nalfurafine on T-
cell effector functions after in vitro and in vivo
exposure.
Non-immune demyelination occurs in the
progressive form of MS and the CPZ-mediated
demyelination model is believed to recapitulate
this pathology. This animal model induces
oligodendrocyte apoptosis and demyelination that
is reproducible in a highly temporal and spatial
manner within the corpus callosum. Although our
results show no significant difference in g-ratio
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between the CPZ and healthy corpus callosum,
there was a significant decrease in the percentage
of myelinated axons in the CPZ corpus callosum. A
clear relationship between axonal diameter and
g-ratio has been reported where larger fibres tend
to have higher g-ratios and, therefore, thinner
myelin sheaths. One of the animals in the healthy
group had an average axonal diameter and g-ratio
Figure 6. Nalfurafine drives remyelination in the cuprizone model of disease. Data are mean  SEM. The 1-way ANOVA with Holm–Sidak’s
multiple comparison test was used for comparing groups. *P < 0.05, **P < 0.01, **P < 0.001, ****P < 0.0001. (a) CPZ treatment timeline. Mice
were fed a cuprizone diet for 42 days to induce demyelination in the brain. The animals were treated with nalfurafine or vehicle 7 days before
the mice returned to standard pelleted chow for the duration of 35 days. (b) Representative electron micrographs of myelin rich areas within the
midline sector of the corpus callosum. Electron micrographs were taken at 5,800 x magnification; 5 images per animal from n = 2 mice per
group were analysed for g-ratio and % myelinated vs unmyelinated axons. At least 200 axons per group were analysed, from at least 20 images
per animal. Scale bar = 2000 nm. (c) Percentage of myelinated and unmyelinated axons of all treatment groups. Myelinated axons #P < 0.05 by
1-way ANOVA with Holm–Sidak’s multiple comparisons test. Unmyelinated axons ***P < 0.001 by 1-way ANOVA with Holm–Sidak’s multiple
comparisons test. (d) Plots of inner axon diameter versus g-ratio (inner axon diameter/outer axon diameter) fit with a linear function. (e) G-ratios
per animal, along the x-axis each individual animal is defined as H (healthy), V (vehicle) or N (nalfurafine). At least 200 axons per group were
analysed, from at least 5 images per animal. Significance is determined per treatment group.
2021 | Vol. 10 | e1234
Page 14
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc.
Nalfurafine drives remyelination L Denny et al.
of 0.714 lm and 0.80, respectively (Supplementary
figure 10). Previous literature has reported that
the average axonal diameter and g-ratio in the
midline section of the murine corpus callosum is
0.6 lm and 0.75, respectively.44,45 This suggests
that larger fibres were analysed in the corpus
callosum of this healthy animal, which could
contribute to the high g-ratio observed. The
corpus callosum from nalfurafine-treated mice
showed a significant decrease in g-ratio in
comparison to vehicle-treated CPZ and healthy
mice, suggesting an increase in myelin thickness.
We also observed an increase in the percentage of
myelinated axons and a decrease in the
percentage of unmyelinated axons, which reflects
what we observed in nalfurafine-treated EAE mice.
These data demonstrate that nalfurafine is capable
of promoting remyelination following non-
immune, as well as immune-mediated
demyelination.
Overall, our results indicate that nalfurafine is
effective over a wide range of doses when
administered therapeutically in EAE with the
0.01 mg kg1 dose providing the greatest and
most sustained rate of recovery, with few relapses
in a KOR-dependent manner. Nalfurafine is also
more effective compared to U50,488 and
maintains therapeutic potential even after chronic
demyelination in EAE. Nalfurafine has a beneficial
effect on neuroinflammation by CD4+ and CD8+ T
cells, which may contribute to functional recovery
seen in EAE, and this reduction in immune cell
infiltration may be enabled by the reduction in
Th1 and Th17 response and shift towards a more
regulatory environment. Finally, this work
highlights the promise of nalfurafine as a
treatment with both neuroprotective and
immunomodulatory potential for MS as
demonstrated by enhanced repair in both




Female C57BL/6J mice (Jackson laboratory; RRID:
IMSR_JAX:000664) were purchased from the Biomedical
Research Unit of the Malaghan Institute of Medical
Research (Wellington, NZ) or bred in-house and housed in
the Victoria University of Wellington PC2 animal facility at
a 14 h dark–10 h light cycle. Food and water were available
ad libitum. Animals were used 8–12 weeks of age for EAE
and 8 to 14 weeks for the cuprizone model.
Ethics statement
All of the experiments with animals were carried out in the
School of Biological Sciences Animal Facility at Victoria
University of Wellington and were approved by the Victoria
University of Wellington Animal Ethics Committee (2014-
R23 & 25295) for EAE and (24383) for cuprizone.
Drugs
Nalfurafine and U50,488 were synthesised using previously
published procedures. Norbinaltorphimine (nor-BNI) (≥ 98%
purity by HPLC) was purchased from Tocris Bioscience
(Bristol, UK).
EAE induction and treatments
Mice were immunised subcutaneously (s.c.) in the rear flanks
with myelin oligodendrocyte glycoprotein (MOG)35–55
peptide (50 µg per mouse; Genescript, Piscataway, NJ USA) in
complete Freund’s adjuvant (Sigma, St. Louis, MO USA)
containing 500 lg per mouse heat-inactivated
Mycobacterium tuberculosis H37Ra (Fort Richard, Auckland,
NZ) and injected intraperitoneally (i.p.) with pertussis toxin
(200 ng per mouse; List Biochemicals, Campbell, CA USA) on
days 0 and 2. In all EAE experiments, mice were weighed and
scored daily by an examiner who was blinded to the
treatment assignment. EAE scoring is as follows: 0, normal; 1,
partial tail paralysis; 2, full tail paralysis; 3, paralysis in one
hind limb; 4, paralysis in both hind limbs; and 5, moribund.
Mice which reached a sustained score of 4.5 (paralysis in both
hind limbs; weakness in front limbs) or above were removed
from the experiment. Treatments were blinded throughout
the experiment and initiated at disease onset (score ≥ 1) or
10 days after peak disease. Mice were allocated consecutively
to each treatment group upon disease onset to ensure the
treatment regime remained even across groups. Drugs and
the vehicle control were administered daily i.p. in saline:
DMSO:Tween80 in a ratio of 8:1:1. Animals were treated
daily either from disease onset or 10 days post-peak with
either nalfurafine (0.1–0.0003 mg kg1 i.p.) or U50,488
(1.6 mg kg1 i.p). Treatment with the selective KOR
antagonist nor-BNI was performed weekly at 10 mg kg1 i.p.
with the first dose on the day of disease onset, followed by
daily KOR treatments from 24 h post-nor-BNI treatment. EAE
experiments following nalfurafine and U50,488 treatment
are collated from a total of 17 independent experiments
(n = 2–7 animals per treatment per experiment). EAE
experiments following nor-BNI and nalfurafine treatment
are collated from 2 independent experiments (n = 4 or 5
animals per treatment per experiment). EAE experiments
following delayed nalfurafine treatment are collated from 3
independent experiments (n = 2–7 animals per treatment per
experiment).
CPZ-induced demyelination
Pelleted chow was ground to a powder using a food
processor and mixed with 0.3% cuprizone (CPZ) (Sigma-
Aldrich). Approximately 25 g of the mixture was placed in
the cages and replaced daily for 42 days. The na€ıve group
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received powdered food with no CPZ. After 42 days of CPZ
intoxication, the animals were returned to standard
pelleted chow.
Between day 35 and 69, drugs were administered vehicle
or nalfurafine (0.01 mg kg1 i.p.) at 5 lL g1 of body
weight daily using a 29-gauge needle. All drugs were
dissolved in a saline:DMSO:Tween80 in a ratio of 8:1:1. The
healthy mice were administered daily vehicle treatment (i.e.
saline:DMSO:Tween80).
Primary cell isolation into single-cell
suspension
Following CO2 euthanasia, brains and spleens were isolated
and processed into a single-cell suspension for flow
cytometry. Brain was mashed through a 70-lm cell strainer
and centrifuged at 760 x g for 5 min. Brain cell pellets were
resuspended in 37% PercollTM (Sigma-Aldrich) gradient and
centrifuged at 760 x g for 30 min without brakes. The
myelin layer was removed, the supernatant removed, and
the pellet resuspended for cell counting.
Spleen was mashed through a 70-lm cell strainer and
centrifuged at 760 x g for 5 min, the pellet was loosened
and red blood cells removed using Red Cell Lysis buffer
(Sigma-Aldrich) for 2 min. The number of viable cells was
counted using the trypan blue exclusion assay. Cells were
cultured at 106 cells mL1 in complete T-cell medium
(Dulbecco’s minimal essential medium, 10% FCS, 100 U
mL1 penicillin plus 100 µg mL1 streptomycin, 10 nM
HEPES, 2 mM L-glutamine, and 50 µM 2-mercaptoethanol; all
from Invitrogen, Carlsbad, CA).
Analysis of cytokines
Splenocytes were plated in complete T-cell medium in a
flat-bottomed 96-well plate (Corning, NY USA) and
stimulated with medium, MOG35–55 peptide (27 µg mL
1) or
Concanavalin A (ConA) (1 mL1; Sigma-Aldrich). Nalfurafine
(50 nM), U50,488 (1 µM), or vehicle (0.01% DMSO) was
added before incubation for 72 h at 37 °C and 5% CO2. For
intracellular cytokine analysis, splenocyte cultures were
stimulated with phorbol 12-myristate 13- acetate (PMA;
50 ng mL1; Sigma-Aldrich) and ionomycin (500 ng mL1;
Sigma-Aldrich) in the presence of GolgiStop/Monensin
(1 µg/106 cells; BD Biosciences, NJ) for 4 h at 37 °C and 5%
CO2 before preparing for flow cytometry.
Flow cytometry
Cells were incubated with Fc Block (1 µg/106 cells; 2.4G2; BD
Biosciences) for 15 min. Extracellular staining was
performed for 30 min on ice using: CD4-BV521 (RM4-5;
BioLegend, San Diego, CA, USA), CD45-BV510 (30-F11;
BioLegend), CD3-APC (17.A2, BioLegend), CD25-PE-Cy7
(PC61; BioLegend), CD8-PerCPCy5.5 (53-6.7; BioLegend),
B220 (RA3-6B2; BD Biosciences), CD11b-PE-Cy7 (M1/70;
BioLegend), Ly6C-PE (HK1.4; BioLegend), Gr1-APC-Cy7 (RB6-
8C5, BioLegend), IA/IE-BV421 (M5/114.15.2, BioLegend), F4/
80-FITC (BM8, BioLegend), CD11c-PerCPCy5.5 (N418,
BioLegend).
After staining for extracellular proteins, cells were fixed
in 4% PFA and permeabilised using 0.1% saponin buffer
containing 0.1% bovine serum albumin. Intracellular
cytokines were detected with IFNc-BV421 (XMG 1.2,
BioLegend), IL-10-PE (54902, BD Bioscience), and IL-17A-
AF647 (TC11-18H10, BioLegend).
Flow cytometry was performed on a BD FACS Canto II
(BD Biosciences) and analysed using FlowJo software
version 10.6 (Treestar Inc., Ashland, OR, USA).
Tissue processing for histology
Following CO2 euthanasia and perfusion with phosphate-
buffered saline (PBS), spinal cords were fixed in 4%
paraformaldehyde overnight at 4 °C. Tissue was cryoprotected
in 15% sucrose, followed by 30% sucrose overnight at 4°C or
until the tissue sank to the bottom of the tube. The sections
were embedded in Cryomatrix embedding resin (Thermo
Fisher Scientific), snap-frozen in isopentane on dry-ice, and
stored at 80 °C. Three transverse 20 µm sections were taken
per animal from descending regions of the cervical spinal
cord, were cut using a Leica CM3050 S cryostat microtome
(Leica Biosystems), mounted on Superfrost Plus slides (Thermo
Fisher Scientific) and stored at 80 °C. Prior to staining, slides
were warmed at room temperature for 15–20 min, and
Cryomatrix embedding medium was removed by immersing
the slides in ddH2O for 5 min.
Black Gold II staining and analysis
Black Gold II Myelin staining (Sigma-Aldrich) was performed
as described by the manufacturer. During myelin analysis,
all samples were blinded from the assessor. To quantify
myelin, the percentage of myelin coverage in the region of
interest (ROI) was calculated. Using ImageJ, images of Black
Gold II-stained sections were converted to an RGB stack,
and the green filter was selected. In the selected ROI
(Supplementary figure 1), the colour was inverted, and a
threshold was set based on healthy controls. The white
matter area was selected, and the percentage area of
myelin stain was measured. The lesion area was determined
by the manual section of lesions in the white matter and
presented as a percentage of total white matter. From this,
the number of lesions was counted. The analysis was carried
out on 2 or 3 sections per animal, and these sections were
averaged to generate a mean value for each animal.
Transmission electron microscopy
Mice assigned for transmission electron microscopy (TEM)
were euthanised by lethal administration of sodium
pentobarbital (ProVet). The mice were transcardially
perfused for approximately 10 min using a prewash (5%
heparin sodium salt in PBS containing 145 nM NaCl, 22 mM
Na2HPO4, 1.8 mM NaH2PO4, pH 7.4) followed by a primary
Karnovsky fixative (0.1 M (CH3)2AsO2Na⋅3H2O, 4% PFA,
0.25% glutaraldehyde, pH 7.4). For the spinal cord: the
whole spinal column was cut out, and the spinal cord was
dissected out. The spinal cord was placed in a secondary
Karnovsky fixative (0.1 M (CH3)2AsO2Na⋅3H2O, 4% PFA,
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2.5% glutaraldehyde, pH 7.4) and left at 4 °C overnight
while gently rocking. A 1-mm3 section of the cervical spinal
cord white matter region was cut. For the brain, the entire
brain was gently removed, and a 1-mm thick coronal
section caudal to bregma was isolated using a brain matrix
block. The midline sector of the corpus callosum from each
coronal brain section was trimmed under a dissecting
microscope. The trimmed samples were washed in sodium
cacodylate buffer (0.1 M (CH3)2AsO2Na⋅3H2O, pH 7.4), and
transferred into osmium tetroxide solution (1% OsO4) for
2.5 h. The samples underwent tertiary fixation in 1% uranyl
acetate for 2 h and were dehydrated through increasing
concentrations of ethanol. The samples were embedded in
epoxy resin (#45359-1EA-F, Sigma, US) for polymerisation at
60 °C for 48 h.
Sectioning and imaging
Semi-thin sections were taken using a glass knife and
stained with toluidine blue to determine the correct region
and orientation. Transverse ultrathin sections (90–60 nm)
were cut with a diamond knife (DiATOME, 45 degrees, 3.5–
4.4 mm), and the samples were stained with lead citrate
and uranyl acetate. Images were taken on a Philips CM100
TEM at the Otago Micro and Nanoscale Imaging unit
located at the University of Otago or a JOEL 2010 TEM at
the MacDiarmid Institute of Victoria University of
Wellington using GATAN software.
Myelin assessment
For both EAE and cuprizone experiments, TEM images were
blinded from the assessor. For g-ratio assessment, the outer
and inner axonal diameter lengths were measured for each
axon across the whole image for EAE samples, and in a
specific ROI (9736 9 8095 nm) for cuprizone samples. Only
complete axons were analysed. The g-ratios were calculated
by dividing the inner axonal diameter by the outer axonal
diameter. The g-ratio analysis was carried out on at least 5
images per animal.
Statistical analyses
All graphs and statistical analyses were generated using
GraphPad Prism 8 (GraphPad Software Inc., La Jolla, CA
USA). Comparisons between two groups were performed
using the non-parametric Mann–Whitney test. For
comparison of more than two groups, 1-way or 2-way
analysis of variance (ANOVA) was used with the
recommended multiple comparison tests as indicated in the
figure legends. Non-parametric analyses of more than two
groups were performed with a Kruskal–Wallis test.
Differences of P < 0.05 were considered significant.
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